Stock Info
NASDAQCMMB
Featured Presentation

Chemomab Corporate Overview

April 2021

Pipeline

CM-101, Pipeline within a Drug

  • Primary Sclerosing Cholangitis
  • Systemic Sclerosis
  • Liver Fibrosis MoA (NASH)

Learn More

Chemomab is a clinical-stage biopharmaceutical company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need.

The company’s lead candidate, CM-101, is a first-in-class monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action.

Chemomab is currently testing CM-101 in three phase 2 studies focusing on the rare indications primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc)

Recent News
Mar 29, 2021

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need,...

Mar 16, 2021

Chemomab Ltd., a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced the...

Mar 15, 2021

TEL-AVIV, Israel, March 15, 2021 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (“Anchiano”; Nasdaq: ANCN) and Chemomab Ltd. (“Chemomab”), a clinical-stage biotech company focused on the...

Information Request

If you would like to stay up to date with the latest news and events, click here.
Thank you for your interest.

Contact for investors: